Affymax, Inc.
4001 Miranda Avenue/4015 Miranda Avenue
Palo Alto,
CA 94304
United States - Map
Phone: 650-812-8700
Fax: 650-424-0832
Web Site: http://www.affymax.com
| Affymax, Inc., a biopharmaceutical company, engages in the development of peptide-based drug candidates to enhance the treatment of serious and life-threatening conditions. The companys lead product candidate, Hematide, is designed to treat anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood cells. It is conducting Phase III clinical trials for the treatment of anemia associated with chronic renal failure, on dialysis, and pre-dialysis. Affymax has a license, manufacturing, and supply agreement with Nektar Therapeutics AL, Corporation to manufacture, develop, and commercialize Hematide. The company was founded in 2001 and is based in Palo Alto, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Ms. Arlene Morris , 55
Chief Exec. Officer, Pres and Exec. Director |
$
792.00K |
$
0 | Mr. Paul B. Cleveland , 52
Chief Financial Officer and Exec. VP of Corp. Devel. |
$
449.00K |
$
0 | Dr. Anne-Marie Duliege M.D., M.S., 50
Chief Medical Officer |
$
482.00K |
$
0 | Dr. Robert F. Venteicher Ph.D., 63
Sr. VP of Technical Operations |
$
401.00K |
$
0 | Mr. Steven Love , 40
VP of Fin. |
$
315.00K |
$
0 |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.29% Nasdaq 
Profile
